NEW IN DRUG TREATMENT OF SOLID TUMORS

Presented and published in 2017 data led to the registration of new drugs or new indications for already registered drugs. Some amendments were made in clinical recommendations of professional oncology societies. The most important changes happened in 2017 in drug treatment of solid tumors are presented in this overview. The new options of adjuvant treatment of melanoma showing good results were introduced in clinical practice. First time median progression free survival after the first line of palliative treatment of non-small cell lung cancer and first line of endocrine treatment of metastatic breast cancer (in combination with CDK4/6 inhibitors) reach 2 years. The results of following clinical trials are briefly presented: FLAURA, ASCEND 4 и 5, ALEX, MONALEESA 2 и 3, MONARCH 2 и 3, ExteNET, OlympiAD.